Chronic obstructive pulmonary disease
Not recruitingStudy of Tozorakimab effectiveness and safety in former smokers with Chronic Obstructive Pulmonary Disease (COPD) who experience disease flare-ups
Study of Tozorakimab effectiveness and safety in former smokers with Chronic Obstructive Pulmonary Disease (COPD) who experience disease flare-ups
- Disease:Chronic obstructive pulmonary disease
- Substances:SalbutamolTozorakimab
Italy- Participants:18–64 years · 65+ years
- Substances:Salbutamol
- Sponsor:AstraZeneca AB










